Blastomycosis medical therapy

Jump to navigation Jump to search

Blastomycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Blastomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Blastomycosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Blastomycosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Blastomycosis medical therapy

CDC on Blastomycosis medical therapy

Blastomycosis medical therapy in the news

Blogs on Blastomycosis medical therapy

Directions to Hospitals Treating Blastomycosis

Risk calculators and risk factors for Blastomycosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]Aditya Ganti M.B.B.S. [3]

Overview

As per the guidelines given by the Infectious Diseases Society of America the appropriate regimen must be guided by the clinical form and severity of disease, as well as the immune status of patient and toxicity of antifungal agents. Only asymptomatic infections are left untreated, otherwise all cases need therapy.

Medical Therapy

Antimicrobial Regimen

  • Blastomycosis
  • Mild to moderate pulmonary blastomycosis[1]
  • Preferred regimen: Itraconazole 200 mg PO q12-24h for 6–12 months
  • Note:Initially oral Itraconazole, 200 mg for 3 days and then q12-24h for 6–12 months, is recommended
  • Moderately severe to severe pulmonary blastomycosis[1]
  • Preferred regimen(1): Lipid amphotericin B (Lipid AmB) 3–5 mg/kg IV q 24h for 1–2 weeks AND Itraconazole 200 mg PO q 12h for 6–12 months
  • Preferred regimen(2): Amphotericin B deoxycholate 0.7–1 mg/kg IV q 24h for 1–2 weeks AND Itraconazole 200 mg PO q 12h for 6–12 months
  • Note: Oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h for 6–12 months, is recommended
  • Mild to moderate disseminated blastomycosis[1]
  • Preferred regimen: Itraconazole 200 mg PO q12-24h for 6–12 months
  • Note(1): Treat osteoarticular disease for 12 months
  • Note(2): Oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h for a total of 6–12 months, is recommended
  • Moderately severe to severe disseminated blastomycosis[1]
  • Preferred regimen(1): Lipid amphotericin B(Lipid AmB) 3–5 mg/kg IV q24h for 1–2 weeks AND Itraconazole 200 mg PO q12h for 6–12 months
  • Preferred regimen(2): Amphotericin B deoxycholate 0.7–1 mg/kg IV q24h for 1–2 weeks AND Itraconazole 200 mg PO q12h for 6–12 months
  • Note: oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h, for a total of 6–12 months, is recommended
  • Immunosuppressed patients[1]
  • Preferred regimen(1): Lipid amphotericin B (Lipid AmB), 3–5 mg/kg IV q24h for 1–2 weeks, AND Itraconazole, 200 mg PO q12h for 12 months
  • Preferred regimen(2): Amphotericin B deoxycholate, 0.7–1 mg/kg IV q24h, for 1–2 weeks, AND Itraconazole, 200 mg POq12h for 12 months
  • Note(1): Oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h, for a total of 12 months, is recommended
  • Note(2): Life-long suppressive treatment may be required if immunosuppression cannot be reversed.
  • Pregnant women[1]
  • Children with mild to moderate disease[1]
  • Preferred regimen: Itraconazole 10 mg/kg PO q24h for 6–12 months
  • Note: Maximum dose 400 mg q24h
  • Children with moderately severe to severe disease[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG; et al. (2008). "Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America". Clin Infect Dis. 46 (12): 1801–12. doi:10.1086/588300. PMID 18462107.

Template:WS